Last week, the US Food & Drug Administration approved marketing for a blood test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, developed by the Pennsylvania-based biotechnology company ...

A new investigation guided by Dr. Erikka Loftfield at the National Cancer Institute identifies tiny molecules in blood and urine that seem to line ... Doctors may check diet with a test In the future, ...

A new blood test that detects a hallmark of Alzheimer's is poised to change the way doctors diagnose and treat the disease. The test, the first of its kind to be cleared by the Food and Drug ...

Physicians would be able to inform eligible families about PFAS testing, and, with parental consent, may order a blood test to check for elevated PFAS levels in eligible children.

The test will initially be available at about 50 American research institutes and hospitals that specialize in Alzheimer’s disease, Goki Ishikawa, head of Fujirebio Holdings Inc., a unit of ...

A blood sample analysis can detect markers of this disease at early stages, providing a cheaper and less invasive option for diagnosis. In clinical trials, the Lumipulse blood test was highly ...

Life is full of challenges, and for many people I know, getting enough water is one of them. This holds true for most Americans, who don’t tend to hydrate enough and, in fact, don’t get even ...

The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment earlier with newly approved drugs that slow the progression of the ...

The test claims to be the first blood-based IVD test in the country cleared by the regulator to help detect those with amyloid pathology associated with the illness. According to the company, this ...

Cerebrospinal fluid tests that compare the ratio of two proteins, pTau217 and beta-amyloid 1-42, can cut the need for PET scans, but the diagnostics rely on samples collected via a lumbar puncture.